Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. (TVRD): 3 pipeline candidates · ~13 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
12.7 months
D/E 0.78 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for Tvardi Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$25.0M
Cash
$19.9M
Quarterly Burn
$5.9M
Runway
12.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| korsuva / kapruvia | Approved |
| tti-101 | Phase 2 |
| tti-109 | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
66
Total value held
$9.5M
| Holder | Shares | Value |
|---|---|---|
| slate path capital lp | 704,118 | $2.2M |
| vanguard capital management llc | 689,416 | $2.2M |
| blackrock, inc. | 388,075 | $1.2M |
| american financial group inc | 223,659 | $711K |
| geode capital management, llc | 182,339 | $580K |
| silvercrest asset management group llc | 101,034 | $321K |
| state street corp | 97,231 | $309K |
| renaissance technologies llc | 92,100 | $293K |
| morgan stanley | 72,894 | $232K |
| ubs group ag | 50,454 | $160K |
Showing top 10 of 66 institutional holders of Tvardi Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Tvardi Therapeutics, Inc.'s pipeline?
Tvardi Therapeutics, Inc. (TVRD) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Tvardi Therapeutics, Inc.'s lead drug candidate?
Tvardi Therapeutics, Inc.'s most advanced tracked candidate is korsuva / kapruvia (Approved) for moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis.
What is Tvardi Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Tvardi Therapeutics, Inc. has approximately 12.7 months of cash runway.
What is Tvardi Therapeutics, Inc.'s market capitalization?
Tvardi Therapeutics, Inc.'s market capitalization is approximately $25.0M.
Who is the CEO of Tvardi Therapeutics, Inc.?
Dr. Imran Alibhai Ph.D. is the chief executive officer of Tvardi Therapeutics, Inc. (TVRD).
Get the full picture on Tvardi Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.